deltatrials
Unknown PHASE2 INTERVENTIONAL NCT00382694

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients

Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03

Sponsor: Nordic Myeloma Study Group

Conditions Multiple Myeloma
Interventions Fludarabine
Updated 5 times since 2017 Last updated: Sep 28, 2006 Started: May 31, 2005 Completion: Dec 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00382694, this PHASE2 trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Nordic Myeloma Study Group, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotUnknown~Sep 2025 – present · 12 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jan 2021 [monthly]

    Unknown Status PHASE2

    First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nordic Myeloma Study Group
Data source: Nordic Myeloma Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations